JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB202417

Anti-iNOS+nNOS antibody [EP16634]

4

(1 Review)

|

(4 Publications)

Rabbit Recombinant Monoclonal iNOS antibody. Suitable for I-ELISA, WB and reacts with Recombinant fragment - Mouse, Mouse, Human, Recombinant full length protein - Human samples. Cited in 4 publications.

View Alternative Names

NOS2A, NOS2, Hepatocyte NOS, Inducible NO synthase, NOS type II, Peptidyl-cysteine S-nitrosylase NOS2, HEP-NOS, Inducible NOS, iNOS

4 Images
Indirect ELISA - Anti-iNOS+nNOS antibody [EP16634] (AB202417)
  • I-ELISA

Supplier Data

Indirect ELISA - Anti-iNOS+nNOS antibody [EP16634] (AB202417)

ELISA analysis of House mouse iNos2 recombinant protein at 1000 ng/mL with ab202417. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody.

Western blot - Anti-iNOS+nNOS antibody [EP16634] (AB202417)
  • WB

Lab

Western blot - Anti-iNOS+nNOS antibody [EP16634] (AB202417)

Blocking and dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-iNOS+nNOS antibody [EP16634] (ab202417) at 1/10000 dilution

Lane 1:

Untreated RAW 264.7 (Mouse macrophage cells transformed with Abelson murine leukemia virus) whole cell lysate at 20 µg

Lane 2:

RAW 264.7 (Mouse macrophage cells transformed with Abelson murine leukemia virus) treated with 0.1 mg/ml LPS for 6 hours whole cell lysate at 20 µg

Secondary

All lanes:

Peroxidase conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

Predicted band size: 131 kDa

Observed band size: 131 kDa

false

Exposure time: 3min

Western blot - Anti-iNOS+nNOS antibody [EP16634] (AB202417)
  • WB

Supplier Data

Western blot - Anti-iNOS+nNOS antibody [EP16634] (AB202417)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

ab181602 was used as a GAPDH loading control.

iNOS is not normally expressed in the brain, but can be induced in the brain after inflammatory, infectious, or other damages (PMID : 11138926, PMID : 16156895, PMID : 10322315).

All lanes:

Western blot - Anti-iNOS+nNOS antibody [EP16634] (ab202417) at 1/1000 dilution

Lane 1:

Mouse hippocampus tissue lysate at 20 µg

Lane 2:

Mouse colon tissue lysate at 20 µg

Lane 3:

Mouse colon cancer tissue lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Observed band size: 131 kDa

false

Exposure time: 180s

Western blot - Anti-iNOS+nNOS antibody [EP16634] (AB202417)
  • WB

Lab

Western blot - Anti-iNOS+nNOS antibody [EP16634] (AB202417)

Blocking and diluting buffer and concentration : 5% NFDM /TBST.

ab205606 was used as a loading control.

All lanes:

Western blot - Anti-iNOS+nNOS antibody [EP16634] (ab202417) at 1/1000 dilution

Lane 1:

C-Myc/DDK tagged full length human NOS1 (nNOS) recombinant protein at 10 ng

Lane 2:

C-Myc/DDK tagged full length human NOS2 (iNOS) recombinant protein at 10 ng

Lane 3:

C-Myc/DDK tagged full length human NOS3 (eNOS) recombinant protein at 10 ng

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Observed band size: 130 kDa,160 kDa

false

Exposure time: 20s

  • Carrier free

    Anti-iNOS+nNOS antibody [EP16634] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EP16634

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Human

Applications

I-ELISA, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

We were unable to detect a positive signal in inflammation‑induced THP‑1 cells. According to published studies (PMID:33553532, PMID: 24477906), human macrophages produce very little detectable iNOS and NO in response to inflammatory stimuli due to epigenetic regulation around the NOS2 transcription start site.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IELISA-species-checked": "guaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" }, "Mouse": { "IELISA-species-checked": "guaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" }, "Rat": { "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" }, "Recombinant fragment - Mouse": { "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Recombinant full length protein - Human": { "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The iNOS and nNOS also called inducible nitric oxide synthase and neuronal nitric oxide synthase are enzymes that produce nitric oxide (NO) a signaling molecule involved in various physiological processes. iNOS and nNOS differ in their expression and regulation. iNOS is found in various tissues and is induced under inflammatory conditions while nNOS is constitutively expressed in neurons. The molecular weights of iNOS and nNOS are approximately 131 kDa and 160 kDa respectively. Both isoforms exist as homodimers facilitating the conversion of L-arginine to L-citrulline and nitric oxide.
Biological function summary

Nitric oxide produced by these synthases acts as a neurotransmitter and an immune mediator. In neurons nNOS-derived NO modulates synaptic plasticity and cognitive function significantly affecting processes such as memory and learning. iNOS-derived NO has roles in host defense and inflammation. During immune responses iNOS expression increases and produces NO to help in pathogen destruction. Both enzymes are part of multi-protein complexes that include cofactors like NADPH FAD FMN and tetrahydrobiopterin all necessary for catalytic activity.

Pathways

The nitric oxide produced by iNOS and nNOS participates in the nitric oxide signaling pathway and the cyclic GMP (cGMP) pathway. Nitric oxide activates soluble guanylate cyclase in the cGMP pathway which in turn regulates various physiological processes including vasodilation. nNOS is related to synaptophysin through neuronal pathways affecting neurotransmitter release and neuronal excitability. iNOS is associated with cytokines like TNF-α and IFN-γ in inflammatory signaling pathways having roles in cell death and immune signaling.

Nitric oxide dysregulation by iNOS and nNOS impacts numerous conditions including neurodegenerative diseases and chronic inflammation. In neurodegenerative diseases like Alzheimer's excessive NO production by nNOS can lead to neurotoxicity. Inflammatory disorders such as rheumatoid arthritis involve increased iNOS expression resulting in high levels of nitric oxide and consequent tissue damage. Both iNOS and nNOS through NO production interact with proteins such as amyloid-beta in Alzheimer’s and with various cytokines in inflammatory disorders.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body (PubMed : 7504305, PubMed : 7531687, PubMed : 7544004, PubMed : 7682706). In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM (PubMed : 25417112). Involved in inflammation, enhances the synthesis of pro-inflammatory mediators such as IL6 and IL8 (PubMed : 19688109).
See full target information NOS2

Additional targets

Nitric oxide synthase, brain

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

Discovery immunology 2:kyad027 PubMed38567068

2024

The glucocorticoid dexamethasone inhibits HIF-1α stabilization and metabolic reprogramming in lipopolysaccharide-stimulated primary macrophages.

Applications

Unspecified application

Species

Unspecified reactive species

Sally A Clayton,Chloe Lockwood,John D O'Neil,Kalbinder K Daley,Sofia Hain,Dina Abdelmottaleb,Oliwia O Bolimowska,Daniel A Tennant,Andrew R Clark

JACS Au 3:2597-2608 PubMed37772175

2023

DNA-Based Hydrogels with Multidrug Sequential Release for Promoting Diabetic Wound Regeneration.

Applications

Unspecified application

Species

Unspecified reactive species

Wei Li,Hui Xie,Liping Gou,Ye Zhou,Hao Wang,Ruoqing Li,Yong Zhang,Shuyun Liu,Jingping Liu,Yanrong Lu,Zhengliang Eric He,Nan Chen,Jiang Li,Ying Zhu,Chengshi Wang,Min Lv

Molecular therapy. Methods & clinical development 21:559-573 PubMed33997104

2021

Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair.

Applications

Unspecified application

Species

Unspecified reactive species

Zineb Bouredji,Dounia Hamoudi,Laetitia Marcadet,Anteneh Argaw,Jérôme Frenette

Molecular medicine reports 12:7561-7 PubMed26459745

2015

Epigenetic modifications of histone H3 during the transdifferentiation of Thy-1(+) Lin(‑) bone marrow cells into hepatocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Xinxin Liao,Yixin Liao,Yantai Zou,Guanhong Li,Caixian Liao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com